TrialProstate cancer and prostatic diseases2026

Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study.

Tangtao Gong et al.PubMed ↗Publisher ↗

No numbers read from the abstract.